Neon Therapeutics, Inc.
Neon Therapeutics, Inc. (NTGN): 4 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.4 months
D/E 1.18 · 0% dilution
Lead: Phase 1
4 candidates
N/A
N/A
A transparent, data-derived signal for Neon Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$15.5M
Quarterly Burn
$14.3M
Runway
3.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| neo-ptc-01 | Preclinical |
| neo-pv-01 | Phase 1 |
| neo-stc-01 | Preclinical |
| neo-sv-01 | Preclinical |
Frequently asked questions
How many drug candidates are in Neon Therapeutics, Inc.'s pipeline?
Neon Therapeutics, Inc. (NTGN) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Neon Therapeutics, Inc.'s lead drug candidate?
Neon Therapeutics, Inc.'s most advanced tracked candidate is neo-ptc-01 (Preclinical) for Solid tumors in patients refractory to checkpoint inhibitors.
What is Neon Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Neon Therapeutics, Inc. has approximately 3.4 months of cash runway.
Who is the CEO of Neon Therapeutics, Inc.?
Massachusetts April is the chief executive officer of Neon Therapeutics, Inc. (NTGN).
Get the full picture on Neon Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.